Download PDF
Thromb Haemost 1963; 09(01): 030-052
DOI: 10.1055/s-0038-1654959
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Investigations on the Nature of Hemophilia A[*]

Eberhard Mammen   *
1   Department of Internal Medicine, University of MarburglLahn (Direktor: Prof. Dr. H. E. Bock)
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

    Permissions and Reprints

Summary

In this paper an inhibitor is described that is found in hemophilic plasma and serum different from any till now described inhibitor. The inhibitor only inhibits prothrombin activation in the “intrinsic clotting systems”. This inhibitor is probably not present in normal human plasma or serum. It is destroyed by ether and freeze drying, is labile to acid and storage at room temperature. It is stable upon dialysis and has not been adsorbed on barium sulfate, aluminum hydroxide or kaolin. It precipitates at 50% v/v saturation with alcohol. The nature of this inhibitor seems to be a protein or lipoprotein.

Factor VIII was isolated from hemophilic plasma. The amount isolated was the same as from normal plasma and the activity properties were not different. Hemophiliacs have normal amounts of factor VIII.

* This investigation was supported by a research grant from the Deutsche Forschungsgemeinschaft.


** Present address: Department of Physiology and Pharmacology, Wayne State University, College of Medicine, Detroit, Michigan, USA.


 

  • References

  • 1 Baker W. R, Seegers W. H. Some Properties of Platelet Cofactor I Concentrates of Bovine Origin. Thrombos. Diathes. haemorrh 04: 342 1960;
    PubMedGoogle Scholar
  • 2 Bergna L. J, Pavlovsky A. Classification of Hemophiliacs with Development of Anticoagulant. Acta haemat 16: 247 1956;
    CrossrefPubMedGoogle Scholar
  • 3 Biggs R. The Inhibitory Effect of Hemophilic Plasma. Brit. J. Haemat 04: 192 1958;
    CrossrefPubMedGoogle Scholar
  • 4 Biggs R. The Treatment of Haemophilic Patients with Animal Antihaemophilic Globulin. Acta haemat 24: 124 1960;
    CrossrefPubMedGoogle Scholar
  • 5 Biggs R, Douglas A. S. The Thromboplastin Generation Test. J. Clin. Path 06: 23 1953;
    CrossrefPubMedGoogle Scholar
  • 6 Blombck M, Nilsson I. M. Treatment of Hemophilia-A with Human Antihemophilic Globulin. Acta Med. Scand 161: 301 1958;
    CrossrefPubMedGoogle Scholar
  • 7 Brinkhous K. M. A Study of the Clotting Defect in Hemophilia: The Delayed Formation of Thrombin. Am. J. Med. Sci 198: 509 1939;
    CrossrefPubMedGoogle Scholar
  • 8 Brinkhous K. M. Physiopathology of Hemophilia. Acta haemat 20: 125 1958;
    CrossrefPubMedGoogle Scholar
  • 9 Conley C. L, Hartmann R. C. A Hemorrhagic Disorder Caused by Circulating Anticoagulant in Patients with Disseminated Lupus Erythematodes. J. Clin. Invest 31: 621 1952;
    PubMedGoogle Scholar
  • 10 Conley C. L, Rathburn H. K, Morse W. I, Robinson J. E. Circulating Anticoagulant as a Cause of Hemorrhagic Diathesis in Man. Bull. Johns Hopkins Hosp 83: 288 1948;
    PubMedGoogle Scholar
  • 11 Deutsch E. Hemmkörperhämophilie. Springer; Wien: 1950
    Google Scholar
  • 12 Deutsch E. Über eine eigentümliche hämorrhagische Diathese: Die Hemmkörperhämophilie. Klin. Wschr 28: 326 1950;
    CrossrefPubMedGoogle Scholar
  • 13 Deutsch E. Die hämophilie-ähnlichen hämorrhagischen Diathesen. Ergebn. inn. Med. Kinderheilk 05: 553 1954;
    PubMedGoogle Scholar
  • 14 Deutsch E. Die Immunkoagulopathien. Mod. Probl. Paediat 03: 77 1958;
    PubMedGoogle Scholar
  • 15 Deutsch E, Mammen E. The Inactivation of Plasmathromboplastin. Thrombos. Diathes. haemorrh 02: 324 1958;
    PubMedGoogle Scholar
  • 16 Duke W. W. A Simple Instrument for Determining the Coagulation-Time of the Blood. Arch. Int. Med 09: 258 1912;
    PubMedGoogle Scholar
  • 17 Egeberg O, Borchgrevink C. F, Hjort P. F. Use of Animal Anti- haemophilic Globulin in Surgery: Exarticulation in the Hip in a Haemophiliac. Acta Med. Scand 167: 415 1960;
    PubMedGoogle Scholar
  • 18 Egli H, Schneider W. Untersuchungen über den Faktor IX. Thrombos. Diathes. haemorrh 07: 523 1962;
    PubMedGoogle Scholar
  • 19 Feissly R, Lüdin A. Action de la cocaine sur les plaquettes sanguines. Helv. physiol. Acta 07: 9 1949;
    PubMedGoogle Scholar
  • 20 Fischer M, Cancura W, Deutsch E. Die Behandlung einer Hämophilie-A mit antihämophilem Globulin vom Schwein. Wiener klin. Wschr 73: 312 1961;
    PubMedGoogle Scholar
  • 21 Folin O, Ciocalteu V. On Tyrosine and Tryptophane Determinations in Proteins. J. Biol. Chem 73: 627 1927;
    PubMedGoogle Scholar
  • 22 Frommeyer W. B, Epstein R. D, Taylor F. H. L. Refractoriness in Hemophilia to Coagulation-Promoting Agents: Whole Blood and Plasma Derivatives. Blood 05: 401 1950;
    PubMedGoogle Scholar
  • 23 Gasser H. Über Hemmkörperhämophilie bei Pemphigus vulgaris. Dtsch. Arch. klin. Med 203: 617 1957;
    PubMedGoogle Scholar
  • 24 Graham J. B, Barrow E. M. The Pathogenesis of Hemophilia. An Experimental Analysis of the Anticephalin Hypothesis in Hemophilic Dogs. J. exp. Med 106: 273 1957;
    PubMedGoogle Scholar
  • 25 Hall M. Haemophilia Complicated by an Acquired Circulating Anticoagulant. A Report of Three Cases. Brit. J. Haemat 07: 340 1961;
    PubMedGoogle Scholar
  • 26 Hardistry R. M. Acquired Haemophilia-Like Disease. J. Clin. Path 07: 26 1954;
    CrossrefPubMedGoogle Scholar
  • 27 Harmison C. R, Seegers W. H. Some Physicochemical Properties of Bovine Autoprothrombin II. J. Biol. Chem. in press. 1962
    PubMedGoogle Scholar
  • 28 Hecht E, Shapiro D. Sphingosine as an Inhibitor of Blood Clotting. Science 125: 1041 1957;
    CrossrefPubMedGoogle Scholar
  • 29 Hitzig W. H, Labhart A, Uehlinger E. Transitorische Hemmkörperhämophilie bei Rheumatismus. Helv. med. Acta 18: 410 1951;
    PubMedGoogle Scholar
  • 30 Hougie C. Pseudo-Haemophilia: An Acquired Hemorrhagic Diathesis Due to a Circulating Anticoagulant. J. Clin. Path 06: 30 1953;
    CrossrefPubMedGoogle Scholar
  • 31 Hougie C. Circulating Anticoagulants. Brit. Med. Bull 11: 16 1955;
    CrossrefPubMedGoogle Scholar
  • 32 Hougie C. Pathogenesis of Haemophilia: A Critical Analysis of the Evidence for the Bridge Anticoagulant. Brit. J. Haemat 05: 177 1959;
    CrossrefPubMedGoogle Scholar
  • 33 Howell W. H. The Condition of the Blood in Hemophilia, Thrombosis and Purpura. Arch. int. Med 13: 76 1914;
    PubMedGoogle Scholar
  • 34 Imdahl H, Egli H, Buscha H. Über die Bedeutung der Cohnschen Plasma-Fraktion I für die operative Behandlung bei der Hämophilie A. Med. Welt 1961; 1821.
    PubMedGoogle Scholar
  • 35 Israels L. G, Foerster J, Zipursky A. A Natural Occurring Inhibitor of the First Stage of Blood Coagulation. Brit. J. Haemat 06: 275 1960;
    CrossrefPubMedGoogle Scholar
  • 36 Johnson F. J, Mammen E. F, Seegers W. H. Prothrombin Utilization Following Addition of Platelet Cofactor I Concentrates to Hemophilic Plasma. Thrombos, Diathes. haemorrh 03: 588 1959;
    PubMedGoogle Scholar
  • 37 Johnson S. A, McClaughry R. I, Seegers W. H. Nature of the Blood Clotting Mechanisms in Hemophilia. J. Mich. State Med. Soc 54: 797 1955;
    PubMedGoogle Scholar
  • 38 Johnson S. A, Rutzky J, Schneider Ch. L, Seegers W. H. Activation of Purified Prothrombin with Hemophilia Plasma. Proc. 4. Congr. Internat. Soc. Hemat. 1952
    PubMedGoogle Scholar
  • 39 Johnson S. A, Seegers W. H. Use of Purified Prothrombin in the Study of Hemophilia and Plasma Thromboplastin Component (PTC) Deficiency. J. Appl. Physiol 06: 429 1954;
    CrossrefPubMedGoogle Scholar
  • 40 Johnson S. A, Seegers W. H. Studies on the Plasma Defect in Hemophilia. Rev. Hémat 09: 529 1954;
    PubMedGoogle Scholar
  • 41 Johnson S. A, Seegers W. H. Platelet Cofactor I Activity in the Hemophiliacs. “Hemophilia and Hemophiloid Diseases”. Edit. Brinkhous K. M. Univ. of North Carolina Press; 1957
    Google Scholar
  • 42 Kewick R. A, Wolf P. A Concentrate of Human Antihemophilic Factor. Its Use in Six Cases of Haemophilia. Lancet 01: 647 1957;
    PubMedGoogle Scholar
  • 43 Kowarzyk H, Marciniak E. The Significance of Prothrombin Derivatives. Proc. 8. Congr. Europ. Soc. Hemat., Vienna. 1961
    PubMedGoogle Scholar
  • 44 Kowarzyk H, Marciniak E. Trombogenezza. Polski Tygod. Lekar 16: 1641 1961;
    PubMedGoogle Scholar
  • 45 Larrieu M. J, Soulier J. P. Deficit en fracteur antihémophilique A chez une fille, associé a un trouble du saignement. Rev. hémat 08: 361 1953;
    PubMedGoogle Scholar
  • 46 Lewis J. H, Ferguson J. H. Hemorrhagic Diathesis Due to PTC (Plasma Thromboplastin Component) Deficiency. Proc. Soc. exp. Biol, and Med 82: 445 1953;
    CrossrefPubMedGoogle Scholar
  • 47 Macfarlane R. G, Biggs R, Bidwell E. Bovine Antihaemophilic Globulin in the Treatment of Haemophilia. Lancet 01: 1316 1954;
    PubMedGoogle Scholar
  • 48 Macfarlane R. G, Mallam P. C, Witts L. J, Bidwell E, Biggs R, Fraenkel G. J, Honey G. E, Taylor K. B. Surgery in Hemophilia: The Use of Animal Antihemophilic Globulin and Human Plasma in Thirteen Cases. Lancet II: 251 1957;
    PubMedGoogle Scholar
  • 49 Mammen E. Isolierung von Plättchencofaktor I (Antihämophiles Globulin), aus Rinderserum. Klin. Wschr 39: 872 1961;
    CrossrefPubMedGoogle Scholar
  • 50 Mammen E. Der Nachweis von Plättchencofaktor I (Faktor VIII) im Serum und seine Isolierung aus Seren. Proc. 8. Congr. Europ. Soc. Hemat. Vienna. 1961
    PubMedGoogle Scholar
  • 51 Mammen E. F, Thomas W. R, Seegers W. H. Activation of Purified Prothrombin to Autoprothrombin I or Autoprothrombin II (Platelet Cofactor II) or Autoprothrombin IÏ-A. Thrombos. Diathes. haemorrh 05: 218 1960;
    PubMedGoogle Scholar
  • 52 Mammen E. F, Yoshinari M, Seegers W. H. Platelet Cofactors as Plasma Components of the Intrinsic Blood Clotting Mechanisms. Thrombos. Diathes. haemorrh 05: 38 1960;
    PubMedGoogle Scholar
  • 53 Marciniak E. Autoprothrombin Activation in Serum. Bull. Acad. Polon. Sei 09: 381 1961;
    PubMedGoogle Scholar
  • 54 Marciniak E, Seegers W. H. Autoprothrombin C: A Second Enzyme from Prothrombin. Canad. J. Biochem. and Physiol 40: 597 1962;
    PubMedGoogle Scholar
  • 55 Mulder E. Bridge Anticoagulant, a New Entity? Thrombos. Diathes. haemorrh 06: 160 1961;
    PubMedGoogle Scholar
  • 56 Munro F. L. Properties of an Anticoagulant Found in the Blood of a Hemophiliac. J. Clin. Invest 25: 422 1946;
    CrossrefPubMedGoogle Scholar
  • 57 Nour-Eldin F, Wilkinson J. F. Bridge Anticoagulant: A Hitherto Unrecognized Blood Clotting Inhibitor in Hemophilic and Christmas Disease Plasma, A Simple Method for its Demonstration. Brit. J. Haemat 04: 38 1958;
    CrossrefPubMedGoogle Scholar
  • 58 Nour-Eldin F, Wilkinson J. F. In Vivo Study on the Relation Between Bridge Anticoagulant and Antihaemophilic Globulin. Brit. J. Haemat 04: 292 1958;
    CrossrefPubMedGoogle Scholar
  • 59 Quick A. J. The Thromboplastin Reagent for the Determination of Prothrombin. Science 92: 112 1940;
    CrossrefPubMedGoogle Scholar
  • 60 Ramot B, Singer K. An Unusual Circulating Anticoagulant in Systemic Lupus Erythematosus. Acta haemat 16: 158 1956;
    CrossrefPubMedGoogle Scholar
  • 61 Robinson H. W, Hogden C. G. The Biuret Reaction in the Determination of Serum Proteins. J. Biol. Chem 135: 707 727 1940;
    PubMedGoogle Scholar
  • 62 Schullze H. E, Schwick G. Die klinische Bedeutung der differenzierten Bestimmung von Prothrombin und Acceleratoren der Blutgerinnung. Medizinische 1953; 1354: 1386.
    PubMedGoogle Scholar
  • 63 Schwick G. Beiträge zur Diagnostik von Gerinnungsfaktoren. Laboratoriumsblätter für medizinische Diagnostik 01: 46 1961;
    PubMedGoogle Scholar
  • 64 Seegers W. H. The Purification of Prothrombin. Rec. Chem. Progress 13: 143 1952;
    PubMedGoogle Scholar
  • 65 Seegers W. H. A Theoretical Consideration of the Blood Clotting Mechanisms in Hemophilia. Schweiz. Med. Wschr 84: 1 1954;
    PubMedGoogle Scholar
  • 66 Seegers W. H. Prothrombin. Harvard University Press; Cambridge, Mass: 1962
    Google Scholar
  • 67 Seegers W. H, Loomis E. C, Vandenbelt J. M. Preparation of Prothrombin Products: Isolation of Prothrombin and its Properties. Arch. Biochem 06: 85 1945;
    PubMedGoogle Scholar
  • 68 Seegers W. H, Mammen E, Lee J. M, Landaburu R. H, Cho M. H, Baker W. J, Shepard R. S. Further Studies on the Purification of Platelet Cofactor I. “Hemophilia and Other Hemorrhagic States”. Edit. Brinkhous K. M. Univ. of North Carolina Press; 1959
    Google Scholar
  • 69 Seegers W. H, Marciniak E. Autoprothrombin C in Irregular Blood Clotting. Thrombos. Diathes. haemorrh 08: 1 1962;
    PubMedGoogle Scholar
  • 70 Seegers W. H, Smith H. P. Factors which Influence the Activity of Purified Thrombin. Am. J. Physiol 137: 348 1942;
    PubMedGoogle Scholar
  • 71 Serafini U. M. The Significance of the Socalled “Bridge Anticoagulant”. “Hemophilia and Other Hemorrhagic States”. Edit. Brinkhous K. M. Univ. of North Carolina Press; 1959
    Google Scholar
  • 72 Shanberge J. N, Gore I. Studies on the Immunologic and Physiologic Activities of Antihemophilic Factor (AHF). J. Lab. Clin. Med 50: 954 1957;
    PubMedGoogle Scholar
  • 73 Singer K, Mond E, Hyman J, Levy R. C. Circulating Anticoagulants in Hemophilia and in Hemophilia-Like Diseases. Blood 05: 1135 1950;
    PubMedGoogle Scholar
  • 74 Spaet T. h. H, Garner E. S. Inactivation of Thromboplastin in Human Blood. J. Clin. Invest 34: 1807 1955;
    CrossrefPubMedGoogle Scholar
  • 75 Spaet T. h. H, Garner E. S. Studies on the Storage Lability of Human Anti-haemophilic Factor. J. Lab. Clin. Med 46: 111 1955;
    PubMedGoogle Scholar
  • 76 Speer R. J, Hill J. M, Maloney M, Roberts A, Prager M. D. An Unusual Coagulation Inhibitor Encountered in Refractory Hemophilia. Am. J. Clin. Path 26: 477 1956;
    CrossrefPubMedGoogle Scholar
  • 77 Tocantins L. M. Antithromboplastic Activity of Normal and Hemophilic Plasmas. Fed. Proc 01: 85 1942;
    PubMedGoogle Scholar
  • 78 Tocantins L. M. Demonstration of Antithromboplastic Activity in Normal and Hemophilic Plasmas. Am. J. Physiol 139: 265 1943;
    PubMedGoogle Scholar
  • 79 Tocantins L. M. Cephalin, Protamine and the Antithromboplastic Activity of Normal and Hemophilic Plasmas. Proc. Soc. exp. Biol, and Med 54: 94 1943;
    CrossrefPubMedGoogle Scholar
  • 80 Tocantins L. M. Anticephalin Activity and the Prothrombin Conversion Rate of Normal and Hemophilic Plasmas. Proc. Soc. exp. Biol, and Med 55: 291 1944;
    CrossrefPubMedGoogle Scholar
  • 81 Tocantins L. M. Hemophilic Syndromes and Hemophilia. Blood 09: 281 1954;
    PubMedGoogle Scholar
  • 82 Tocantins L. M. Discussion to Inhibitors in Hemophilia. “Progress in Coagulation”. Schattauer, Stuttgart, 1962: 100.
    PubMedGoogle Scholar
  • 83 Tocantins L. M, Carroll R. T. Coagulation Decelerating Action of Hemophilic Plasma on Normal Plasma. Fed. Proc 08: 157 1949;
    PubMedGoogle Scholar
  • 84 Tocantins L. M, Carroll R. T, Holburn R. R. Clot Accelerating Effect of Dilution on Blood and Plasma. Relation to the Mechanism of Coagulation of Normal and Hemophilic Blood. Blood 06: 720 1951;
    PubMedGoogle Scholar
  • 85 Ulutin O. N, Seegers W. H. Antithrombin II Anticoagulant (Autoprothrombin II-A). Thrombos. Diathes. haemorrh 06: 270 1961;
    PubMedGoogle Scholar
  • 86 Ware A. G, Seegers W. H. Two-Stage Procedure for the Quantitative Determination of Prothrombin Concentrations. Am. J. Clin. Path 19: 471 1949;
    CrossrefPubMedGoogle Scholar
  • 87 Windörfer A, Schultze H. E, Schwick G. Immuno-Hemmkörper- hämophilie-A. Blut 02: 217 1956;
    CrossrefPubMedGoogle Scholar
  • 88 Zbinden T, Leupold R. Über Hemmkörperhämophilie. Schweiz. Med. Wschr 87: 1478 1957;
    PubMedGoogle Scholar